Christopher W Chiu

4PUBLICATIONS
18CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Feb 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma.

Tommy Li, Leonid Gibiansky, Apurvasena Parikh

|May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Maissa Mhibik, Erika M Gaglione, David Eik

|Dec 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres

|Aug 23, 2022
Semimechanistic Physiologically-Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B-Cell Lymphomas.

Tommy Li, Ida H Hiemstra, Christopher Chiu

Pageof 1

Frequent Collaborators

2 joint publications

Tommy Li

1 joint publications

Catherine Thieblemont

1 joint publications

Tycel Phillips

1 joint publications

Herve Ghesquieres